Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "Anticholinergic Drugs" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antispasmodic drugs with an anticholinergic effect include: Bentyl (dicyclomine) Buscopan (hyoscine butylbromide) Levsin (hyoscyamine) Lomotil (atropine/diphenoxylate) Enablex (darifenacin) Pamine (methylscopalamine) Spiriva (tiotropium bromide)
Compositions and methods of decreasing nicotine withdrawal
InactiveUS20050227998A1Relieve symptomsMinimizing nicotine withdrawal symptomBiocideData processing applicationsAnticholinergic DrugsHydroxyzine
Administering to a patient an anticholinergic medication comprising scopolamine and hydroxyzine can alleviate the symptoms of nicotine withdrawal. Used in conjunction with pre- and post-administration counseling, smoking cessation rates may be significantly improved.
Owner:VOELKER KIRK
Treatment of diseases modulated by a h4 receptor agonist
The invention provides a method for the treatment of H4R modulated diseases and / or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.
Owner:NICOLAOU MICHALIS +3
Compositions for treatment of common cold
InactiveUS7652030B2Efficient dosingReducing the runny noseBiocideAerosol deliveryCommon coldAnticholinergic Drugs
New stable compositions comprising the combination of a topically active vasoconstrictor and a topically active anticholinergic drug are disclosed. Preferably, the composition comprises ipratropium or a salt thereof in combination with xylometazoline hydrochloride and a salt thereof. Upon topically administering such compositions to a nasal mucosa in individuals suffering from the common cold the symptoms of rhinorrhea are significantly reduced.
Owner:TAKEDA PHARMA AS
Quininone reductase and application thereof to asymmetric synthesis of (R)-3-quinuclidinol
ActiveCN103555608AIncrease concentrationMild reaction conditionsBacteriaMicroorganism based processesAnticholinergic DrugsEnantioselective synthesis
The invention discloses anagrobacterium radiobacter, a quininone reductase expressed thereby and a gene thereof, recombinant expression plasmid containing the gene, recombinant expression vector containing the gene, a recombinase of quininone, a preparation method of the recombinase , and application of the recombinase to asymmetric reduction of 3-quininone as a catalyst for preparation of (R)-3-quinuclidinol. Compared with other preparation methods for (R)-3-quinuclidinol, the (R)-3-quinuclidinol prepared by employing the quininone reductase provided by the invention is not only high in product concentration, but also good in optical purity; the reaction condition is mild, the operation is convenient, and the preparation is easy to amplify; and therefore the application of the quininone reductase to asymmetric synthesis of (R)-3-quinuclidinol has extremely good industrial application prospect in the production of intermediates of anticholinergic drugs.
Owner:EAST CHINA UNIV OF SCI & TECH
HFC solution formulations containing an anticholinergic
Owner:BOEHRINGER INGELHEIM INT GMBH
Treatment of diseases modulated by a H4 receptor agonist
Owner:NICOLAOU MICHALIS +3
Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
InactiveUS20080027094A1Eliminate side effectsReduce adverse reactionsBiocideOrganic chemistrySide effectAnticholinergic Drugs
The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X− is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and / or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
Owner:ONO PHARMA CO LTD
Dry powder formulation comprising an anticholinergic drug
Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and / or treatment of a respiratory disease such as asthma and COPD.
Owner:CHIESI FARM SPA
Pharmaceutical composition
InactiveUS20060110449A1Reduce adverse effectsImproved degradation profileBiocideSenses disorderDiseaseAnticholinergic Drugs
Owner:SCHERING CORP
Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances
InactiveCN103495172AGood effectControl withdrawal symptomsOrganic active ingredientsNervous disorderBenzodiazepineDrug withdrawal symptoms
The invention discloses a medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances. The medicament is prepared from the following components by weight percent: 2-95% of antipsychotics, 0.001-5% of alpha2 adrenergic agonists, 0-5% of anticholinergic agent, 0-80% of nonopioid analgesic, and 0-10% of benzodiazepine. The pharmaceutical composition disclosed by the invention achieves an ideal effect when the symptoms of a sufferer abusing stimulants such as benzedrine, or abusing the opiates substances in a merging manner are treated; the withdrawal symptom can be rapidly and obviously controlled; the detoxification recovery rate can be up to over 90%.
Owner:卢正堂 +1
Anticholinergic pharmaceutical composition
ActiveCN103553996AEfficient removalImprove stabilityOrganic chemistryDigestive systemAnticholinergic DrugsDuodenal ulcer
The invention relates to an anticholinergic pharmaceutical composition. Specifically, the invention relates to a medicament capable of being used in pharmacy, wherein the,medicament comprises a compound expressed by the following formula. The invention further provides a preparation of the medicament, and the medicament and the preparation are used as an anticholinergic medicament and can be clinically used for anesthesia, peptic ulcer, salivation, etc. The raw material medicament or preparation has the function of inhibiting gastric secretion and regulating gastrointestinal peristalsis; the raw material medicament or preparation has relatively strong salivary secretion resistance than atropine while having no central anticholinergic activity. The anticholinergic pharmaceutical composition is generally used for clinically treating such symptoms as gastric and duodenal ulcer, chronic gastritis and excessive secretion of gastric acid.
Owner:HUNAN DONGTING PHARMA
Pharmaceutical composition preparation
InactiveCN111467498AReduce exacerbationsImprove lung functionRespiratory disorderHeterocyclic compound active ingredientsAnticholinergic DrugsGlucocorticoid
The invention provides a pharmaceutical composition preparation. The pharmaceutical composition preparation comprises an anticholinergic drug tiotropium or a hydrate thereof, a beta 2-receptor agonistarformoterol or a salt thereof, and an inhaled glucocorticoid fluticasone or an ester derivative thereof; tiotropium bromide acts on a muscarinic receptor on bronchial smooth muscles, the cholinergiceffect of acetylcholine released by the tail ends of parasympathetic nerves can be inhibited, and muscular tension is blocked; the arformoterol acts on a beta 2-receptor on an airway smooth muscle cell membrane, so that the release of degranulation and media of mast cells and basophils is reduced, the permeability of capillaries is reduced, and swinging of airway epithelial cilia is increased; the fluticasone is an effective anti-inflammatory drug, and when the three drugs are combined for use, the three mechanisms jointly exert the bronchus relaxing effect and the anti-inflammatory effect; the application range of the triple therapy is wider on the important clinical indexes of reducing acute exacerbation of patients suffering from chronic obstructive pulmonary disease, reducing total-cause mortality rate, improving the lung function of the patients suffering from chronic obstructive pulmonary disease, improving the living quality and the like.
Owner:王兆霖
Oligomer-Anticholinergic Agent Conjugates
The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer.
Owner:NEKTAR THERAPEUTICS INC
Application of radix physochlainae extract in preparation of drugs for preventing and treating myopia
InactiveCN111358855AGood treatment effectImprove securitySenses disorderPharmaceutical delivery mechanismL-HyoscyamineAnticholinergic Drugs
The invention provides application of a radix physochlainae extract in preparation of drugs for preventing and treating myopia. Effective compositions such as anisodamine, scopolamine and scopoletin in the radix physochlainae extract are obtained through tests, the purpose of preventing and treating myopia can be achieved, and the defect that clinical application cannot be achieved due to potential side effects caused by long-term single use of anticholinergic drugs can be effectively overcome. The radix physochlainae extract has a remarkable treatment effect on myopia, is high in safety, andis expected to be popularized and applied clinically. Experiments prove that the radix physochlainae extract can be used for improving myopia by regulating scleral fibrous layers and retinal pigment cells, influencing expression of matrix metalloproteinase 2, matrix metalloproteinase inhibitor 2 and the like, regulating spasm of ciliary muscles and the like. The invention also provides a composition. The composition comprises effective components of the radix physochlainae extract; and the composition provides a new way for preventing and treating myopia.
Owner:毕宏生
Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome
ActiveCN101829328AGood effectControl withdrawal symptomsOrganic active ingredientsNervous disorderBenzodiazepineDrug withdrawal symptoms
The invention relates to a drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome, which comprises the following components in percent by weight: 2-95 percent of antipsychotics, 0.001-5 percent of a2 adrenergic receptor agonist, 0-5 percent of anticholinergic drug, 0-80 percent of non-opiates pain easing agent and 0-10 percent of benzodiazepines drugs. When used for treating symptoms occurring in patients abusing exhilarants of Benzedrine and the like or integrally abusing opioid, the drug achieves better effect, can rapidly and remarkably control abstinence syndrome, and has detoxification cure rate reaching over 90 percent.
Owner:卢正堂 +1
Rhinitis Treatment Regimens
ActiveUS20080058366A1Reduce confusionEliminate the effects ofBiocideAnimal repellantsAnticholinergic agentsTreatment regimen
A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent. A pharmaceutical package for treating rhinitis with rhinorrhea includes a daytime dosage unit containing a medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent, indicia to distinguish between the daytime dosage unit and the nighttime dosage unit, instructions for coordinating the daytime dosage unit and the nighttime dosage unit as a treatment regimen for treating rhinitis with rhinorrhea, and a unifying container for housing the daytime dosage unit, the nighttime dosage unit, the indicia, and the instructions.
Owner:PHARMA DESIGN
Vilanterol trifluoromethanesulfonate-containing pharmaceutical preparation
InactiveCN103933049AReduce the number of acute exacerbationsImprove lung functionOrganic active ingredientsAntipyreticAnticholinergic DrugsGlucocorticoid
The invention discloses a vilanterol trifluoromethanesulfonate-containing pharmaceutical preparation, which comprises the following main active ingredients: long-acting beta2 receptor agonist vilanterol trifluoromethanesulfonate, glucocorticoid drug fluticasone furoate and long-acting anticholinergic drug aclidinium bromide, or physiologically acceptable salts of the fluticasone furoate and aclidinium bromide, thus composing a compound preparation. The vilanterol trifluoromethanesulfonate has the effect of continuously dilating blood vessels for 24 hours; the fluticasone furoate is fast-acting potent glucocorticoid, and the duration time of the drug is longer than that of other glucocorticoids; the aclidinium bromide is long-acting cholinergic receptor antagonist, and combines with beta2 receptor agonist so as to play roles of synergism and reduction of adverse drug reaction. The vilanterol trifluoromethanesulfonate, the fluticasone furoate and the aclidinium bromide are combined for use to prepare an inhalable compound preparation which can be taken once daily due to 24-hour acting. The vilanterol trifluoromethanesulfonate-containing pharmaceutical preparation can enhance the curative effect, solves the compliance problem of patients with coexisting chronic obstructive pulmonary disease and asthma, thus being appreciable in application prospects.
Owner:SHANGHAI NEW ASIA PHARMA +1
Anti-Nicotine Treatment
InactiveUS20070287727A1Reduce initial withdrawal symptomMinimize long-term relapse rateBiocideAnimal repellantsAnticholinergic DrugsAnticholinergic agents
A method is described for treatment of nicotine dependency and cessation or reduction of tobacco use in humans which combines pharmacotherapy designed to ameliorate the initial withdrawal symptoms followed by behavioral modification intended to minimize the relapse rate. Pharmacotherapy consists of the use of anticholinergic agents, which facilitate a smooth withdrawal from nicotine. A composition is described comprising scopolamine, glycopyrrolate and benztropine which is injected parenterally. In addition the individuals participate in weekly counseling sessions for at least 4 weeks after treatment.
Owner:HYTHIAM
Pharmaceutical formulation comprising an anticholinergic drug
InactiveUS20090180969A1Significant comprehensive benefitsOrganic active ingredientsDispersion deliveryAnticholinergic DrugsPharmaceutical formulation
Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and / or treatment of an obstructive airways disease.
Owner:CHIESI FARM SPA
Surfactant-containing spray of anticholinergic drug
The invention relates to a medicine tiotropium bromide spray for treating respiratory diseases, especially asthma, chronic obstructive pneumonia, trachitis and the like. An inhalable surfactant enables the spray particle size, spray time and spray speed of the composition to be more suitable by adjusting the surface tension of a spray pharmaceutical composition of M1, M2 and / or M3 receptor anticholinergic drugs without propellants.
Owner:TIANJIN JINYAO GRP
Inhalation solutions
Owner:CIPLA LTD
Compositions for opiate and opioid prevention and reversal, and methods of their use
InactiveUS20220160704A2Improve impactAchieve rapidityNervous disorderAntinoxious agentsAdrenergic antagonistLaryngospasm
Owner:TORRALVA MEDICAL THERAPEUTICS LLC
Pharmaceutical compound, its preparation method and application in making medicine
InactiveCN1785997AReduce frequencyLow cost of treatmentOrganic active ingredientsOrganic chemistryDiseasePharmacy
The present invention relates to a bromo-1-cyclopropylmethyl-3-(2-phenyl-2-cyclopentyl-2-hydroxyoxyethyl) quinuclidane medicine compound, its preparation method and application of said medicine compound in preparation of anticholinergic and medicine for curing respiratory diseases. The invented medicine compound can selectively act on receptor M1 and receptor M3 and does not act on receptor M2, and is not easy to permeate through blood-brain barrier, so that it can reduce pharmacy frequency of patient and can reduce therapeutic cost.
Owner:CHENGDU LIST PHARMA
Combined drug for treating psoriasis and application of combined drug
InactiveCN110898227AHydroxy compound active ingredientsDermatological disorderPsoriasis patientSedative drug
The invention provides a combined drug for treating psoriasis. The combined drug includes an anticholinergic drug and a sedative drug used in combination. According to the combined drug provided by the invention, the anticholinergic drug and the sedative drug are used according to a specific ratio, so that the treatment effect can be effectively enhanced, onset of psoriasis patients can be delayed, and the degree of skin damage to scalps, nails, hands and feet can be improved; the combined drug provided by the invention has little or no side effects and high safety; and at the same time, the combined drug provided by the invention can effectively treat the psoriasis, the effect is better than that of an anticholinergic drug scopolamine alone, so that results indicate that the drug providedby the invention has a synergistic effect when used in combination according to the specific ratio, and has a good clinical application prospect.
Owner:LUWAN BRANCH OF RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Method for treating incontinence
InactiveUS20020142033A1Reduce morbidityDecrease dry-mouthOrganic active ingredientsOsmotic deliveryAnticholinergic agentsAnticholinergic Drugs
Owner:GUPTA SUNEEL K +2
Method capable of simultaneously detecting various anticholinergic drugs
InactiveCN110231391AReduce consumptionEfficient Separation AnalysisMaterial analysis by electric/magnetic meansAnticholinergic DrugsAtropine
The invention discloses a method capable of simultaneously detecting various anticholinergic drugs. The anticholinergic drugs at least comprise atropine, anisodamine, scopolamine methobromide and scopolamine butylbromide; the detection method adopts CE-ESI-MS (Capillary Electrophoresis-Electrospray mass spectrometry), in the detection process, the separation voltage, the buffer solution, the sheath fluid type and the sheath fluid flow velocity parameter are set as follows: the separation voltage is 10-21 kV; the buffer solution is an ammonium acetate buffer solution with a pH value of 9.4, thesheath fluid type is an isopropanol-aqueous solution added with acetic acid, and the sheath fluid flow velocity is 2.0-4.0 [mu]L / min. According to the scheme, high-efficiency and rapid separation andanalysis can be realized by adopting a CE-MS coupling technique, thereby reducing the consumption of an organic solvent; compared with an HPLC-MS (High Performance Liquid Chromatography-Mass Spectrometry) technique in the prior art, the method has the advantages of being small in sample amount and the like; and the scheme in the invention is combined with high-efficiency separation of capillary electrophoresis and an accurate qualitative function of mass spectra, so that the detection result is more accurate.
Owner:GUILIN UNIVERSITY OF TECHNOLOGY
Method for preventing human glands from radiation injury
PendingCN114746107AAvoid damagePrevent permanentIn-vivo radioactive preparationsPeptide/protein ingredientsAnticholinergic DrugsSide effect
The invention relates to the field of radiooncology. The methods according to the invention comprise the use of botulinum toxins and anticholinergic agents to prevent glands from radiation damage and side effects due to radioactive ligands. The method according to the invention further comprises the use of botulinum toxins to prevent the glands from radiation damage, wherein the radiation damage is caused by radioactive ligands. By using the method according to the invention, the invention can provide effective protection of the glands to avoid radiation damage.
Owner:MERZ THERAPEUTICS GMBH
Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
PendingUS20220096467A1Organic active ingredientsSenses disorderAnticholinergic DrugsAdrenergic receptor agonists
The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders.
Owner:CELLIXBIO PTE LTD
Combined drug for treating chronic, intractable or primary insomnia and application thereof
InactiveCN111135304ANervous disorderHydroxy compound active ingredientsSedative drugAnticholinergic Drugs
The invention provides a combined drug for treating chronic, intractable or primary insomnia. The combined drug comprises an anticholinergic drug and a sedative drug which are combined for use. According to the invention, the anticholinergic drug and the sedative drug are used according to a specific ratio, so the treatment effect can be effectively enhanced, and the morbidity of chronic, intractable or primary insomnia patients is delayed. The combined drug provided by the invention is small in side effects or free of side effects and high in safety. Meanwhile, the combined drug provided by the invention can effectively treat the chronic, intractable or primary insomnia; the effect of the combine drug is superior to the effect of dexmedetomidine for independent use; thus, the combined drug is indicated to have a synergistic effect in combined use in a specific ratio and have good clinical application prospect.
Owner:李启芳
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com